On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Purdue and Eisai team up on insomnia drug; Bristol-Myers inks another immuno-oncology deal;

@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech @JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout....

Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies

NEW YORK & QUEENSLAND, Australia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license...

Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant

WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have...

Neurovive Pharmaceutical: NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

STOCKHOLM--Regulatory News: CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held...

FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...

Sanofi buys into Google's biotech future, pairing up in diabetes

Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.

Google's life sciences team's first major area of focus: diabetes

August 31, 2015 People living with diabetes have to keep their blood sugar levels in a normal range using a combination of diet, exercise, and medication. Yet even today, this involves a surprising...

Intercept wins priority review for OCA

The FDA granted Intercept's obeticholic acid (OCA) application for primary biliary cirrhosis a priority review, setting the PDUFA date at February 29, 2016.

Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases

Bristol-Myers Squibb Company (BMY) and Promedior, Inc. announced the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain...